{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:50:45Z","timestamp":1789012245501,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.critrevonc.2022.103807","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T12:26:28Z","timestamp":1662553588000},"page":"103807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R\/R ALL and NHL: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"179","author":[{"given":"Sifei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runkai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2022.103807_bib1","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103807_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002328","article-title":"Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells","volume":"9","author":"Bai","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"10266","key":"10.1016\/j.critrevonc.2022.103807_bib3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.critrevonc.2022.103807_bib4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103807_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an Anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103807_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eng.2018.12.006","article-title":"Donor-derived CD19-targeted T cell infusion eliminates B cell acute lymphoblastic leukemia minimal residual disease with no response to donor lymphocytes after allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Cheng","year":"2019","journal-title":"Engineering"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103807_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103807_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103807_bib9","unstructured":"FDA, 2022. Human Gene Therapy Products Incorporating Human Genome Editing. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-products-incorporating-human-genome-editing\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103807_bib10","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103807_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transpl."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103807_bib12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41375-019-0610-x","article-title":"HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation","volume":"34","author":"Jin","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103807_bib13","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103807_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood.V128.22.281.281","article-title":"Cars in leukemia: relapse with antigen-negative leukemia originating from a single B cell expressing the leukemia-targeting CAR","volume":"128","author":"Lacey","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103807_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2021-146045","article-title":"ALPHA2 study: ALLO-501A allogeneic CAR T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing","volume":"138","author":"Lekakis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103807_bib16","article-title":"Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103807_bib17","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103807_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103807_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid. Based Med."},{"key":"10.1016\/j.critrevonc.2022.103807_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103807_bib21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103807_bib22","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2021-146038","article-title":"ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory Non-Hodgkin's lymphoma comparable to autologous CAR T","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103807_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103807_bib24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood-2019-129640","article-title":"Automated manufacture of matched donor-derived allogeneic CD19 CAR T-cells for relapsed\/refractory B-ALL following allogeneic stem cell transplantation: toxicity, efficacy and the important role of lymphodepletion","volume":"134","author":"Roddie","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103807_bib25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2022.103807_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2021-150609","article-title":"Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in patients with relapsed\/refractory B-cell malignancies","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103807_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103807_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/imt-2020-0221","article-title":"Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2021","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103807_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CJI.0000000000000257","article-title":"Chimeric antigen receptor-modified donor lymphocyte infusion improves the survival of acute lymphoblastic leukemia patients with relapsed diseases after allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Wang","year":"2019","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103807_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2022.103807_bib31","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2022.103807_bib32","article-title":"Consolidative hematopoietic stem cell transplantation after CD19 CAR-T cell therapy for acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103807_bib33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hon.2682","article-title":"Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Yang","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103807_bib34","first-page":"OF1","article-title":"Next-generation CAR T-cell therapies","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103807_bib35","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","article-title":"Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant","volume":"35","author":"Zhang","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2022.103807_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-133486","article-title":"Long-term outcomes following donor-derived anti-CD19 CAR-T cell therapy for B-Cell acute lymphoblastic leukemia patients relapsed after allogenic stem cell transplantation","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103807_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139390","article-title":"Feasibility, and efficacy of donor-derived cd19-targeted Car t-Cell therapy in refractory\/relapsed (r\/r) b-cell acute lymphoblastic leukemia (b-all) patients","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103807_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41375-021-01351-w","article-title":"Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Zhao","year":"2022","journal-title":"Leukemia"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:46:20Z","timestamp":1760903180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822002311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"alternative-id":["S1040842822002311"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103807","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R\/R ALL and NHL: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103807"}}